Multiple sclerosis treatment: building a plan for attacks, progression, and everyday function

A useful multiple sclerosis treatment plan answers several different questions. Is the diagnosis secure? Is there a current inflammatory attack that needs attention? What treatment could reduce future disease activity or disability accumulation? Which symptoms interfere with work, sleep, relationships, or independence today? Those questions overlap, but a single medicine or a reassuring scan rarely settles all of them.

Key takeaways

These excerpts come from the original article. Read the full sections below for context.

Before comparing treatments, ask the neurologist to explain the evidence supporting MS. The answer should connect the clinical history, examination, relevant imaging, and any spinal-fluid or other laboratory findings. A phrase such as “white-matter changes” on a scan is not enough by itself. The location and appearance of abnormalities, the way symptoms developed, and the possibility of another cause all matter.
Relapsing-remitting MS, secondary progressive MS, and primary progressive MS describe different clinical courses. Current inflammatory activity adds another layer. Patients should ask for the course and activity assessment to be recorded clearly, with the observations supporting it. A referral that says only “MS” can leave the receiving clinician without information essential to interpreting previous treatment decisions.
For a consultation in China, prepare original brain and spinal imaging, reports, a dated attack history, spinal-fluid findings, relevant antibody results, and a complete treatment record. Include medicines stopped because of adverse effects, the dates involved, and the response after stopping. A current prescription alone may conceal the information needed to understand an earlier treatment failure.

Quick answer

Full guide

Multiple sclerosis, or MS, affects the central nervous system, including the brain, spinal cord, and optic nerves. Inflammation and damage to myelin and nerve structures can produce very different combinations of problems. Someone recovering from optic neuritis may have different priorities from a person whose walking has gradually deteriorated without a recent attack. Current care can modify disease activity in suitable patients and improve aspects of daily life; it cannot promise to reverse every established injury. The Chinese clinical guideline provides a local framework for diagnosis and management, although its publication date matters when assessing subsequent changes. Chinese MS diagnosis and treatment guideline, 2023 edition

Establish what the diagnosis rests on

Before comparing treatments, ask the neurologist to explain the evidence supporting MS. The answer should connect the clinical history, examination, relevant imaging, and any spinal-fluid or other laboratory findings. A phrase such as “white-matter changes” on a scan is not enough by itself. The location and appearance of abnormalities, the way symptoms developed, and the possibility of another cause all matter.

The 2024 revision of the McDonald diagnostic criteria was published in 2025. It adds the optic nerve as a fifth anatomical location and permits additional evidence within defined diagnostic pathways. Consequently, waiting for a second obvious attack is no longer a universal requirement. Equally, the expanded criteria do not make every incidental brain lesion diagnostic of MS. Their purpose is a sufficiently specific clinical diagnosis, not a checklist that patients should apply to themselves. Original revised McDonald criteria

This distinction has practical consequences when seeking a second opinion in China. Bring the original scan files, not only photographs of the radiology report. Describe each possible attack separately: what changed, how rapidly it developed, how long it lasted, and how much recovery occurred. A specialist may interpret the same report differently after reviewing the images or learning that symptoms had another plausible explanation.

Some patients need evaluation for neuromyelitis optica spectrum disorder or MOG antibody-associated disease. These conditions can overlap with MS in the kinds of symptoms they produce, but their disease mechanisms and treatment pathways are distinct. Antibody testing should answer a clinical question; a positive result, especially in an unsuitable clinical context, is not a substitute for a full assessment. If the proposed diagnosis changes, ask which finding prompted that change and how it affects the treatment recommendation. NEMOS differential-diagnosis recommendations, International MOGAD diagnostic criteria

Decide whether current worsening represents an attack

New visual loss, weakness, sensory change, or another neurological problem deserves assessment. The team will consider whether the pattern suggests new inflammatory activity, a recurrence of old symptoms during infection or heat exposure, an unrelated illness, or a combination. Recording temperature, infection symptoms, medication changes, and the timing of deterioration can help the assessment. It does not replace an examination when one is needed.

Contact the treating service promptly when a suspected attack is affecting vision, walking, or self-care. Abrupt major weakness, speech disturbance, or serious systemic illness also warrants urgent evaluation for other conditions. Having an MS diagnosis does not mean that every new neurological symptom must be caused by MS. A routine appointment several weeks away may be the wrong route for an acute problem. NICE MS management recommendations, updated in 2026

Clinicians may consider corticosteroid treatment for a confirmed relapse that is sufficiently troublesome or functionally important. A mild event does not always require the same response. Previous problems with blood glucose, sleep, mood, or infection should be discussed before treatment. Repeatedly using a leftover steroid prescription whenever fatigue increases is not an appropriate substitute for identifying the cause of deterioration.

The decision after recovery is separate. Did this event occur before a long-term medicine had time to work? Was treatment interrupted? Does the episode, together with imaging and previous activity, suggest inadequate disease control? Those questions determine whether to continue, investigate further, or reconsider the maintenance strategy. Recovery from one attack does not by itself establish that the longer-term plan is adequate.

Recognize progression even when relapses are absent

Some people notice gradual deterioration rather than distinct episodes. They may take longer to walk a familiar route, need more help with buttons, or find that cognitive tasks consume much more effort. The neurologist needs to know about those changes even when there has been no clear relapse. No recent attack, no new MRI lesion, and no functional progression are different observations.

A review should also look for treatable contributors. Pain, poor sleep, depression, medication effects, reduced physical activity, and other illnesses can worsen performance. Identifying one of these factors does not imply that the symptoms are unimportant or imagined. It creates another opportunity to improve function while the team continues to assess the course of MS.

It helps to bring concrete comparisons. “I now need two rests between my apartment and the shop” is more useful than “walking is worse.” The same principle applies to hand function, continence, concentration, and fatigue. A plan can then include both disease assessment and a practical target, such as completing a specific daily task more safely.

Choose disease-modifying treatment around the individual situation

Disease-modifying therapy, commonly called DMT, has a different purpose from medicine used for pain, spasticity, or an acute attack. The choice depends on the disease course, inflammatory activity, previous response, safety factors, reproductive plans, and the monitoring that can realistically be sustained. Route of administration matters, but an oral medicine is not automatically safer and an infusion is not automatically more effective for every person. American Academy of Neurology DMT practice guideline

Some patients should discuss an earlier high-efficacy strategy. The relevant question is how the expected benefit compares with the risks and burdens in their own situation. A 2025 expert consensus supports careful consideration of early high-efficacy treatment, but consensus is not a universal instruction to give every newly diagnosed patient an identical drug. Ask which features of your illness favor the proposed approach and what would lead the clinician to revise it. 2025 early high-efficacy treatment consensus

Practical constraints deserve the same clarity. A person who lives far from a laboratory may have difficulty with frequent monitoring. Someone who travels regularly may need a reliable arrangement for medicine storage and refills. A less frequent administration schedule may still require infection screening, blood tests, or prompt assessment of new symptoms. These are elements of treatment feasibility, rather than optional administrative details.

Before agreeing, ask for the expected review points. What will establish the treatment baseline? When will symptoms and imaging be reassessed? Which adverse effects should be reported before the next scheduled visit? If a switch becomes necessary, who will plan the transition? A written plan is particularly valuable when more than one country or health system will be involved.

Understand the options for progressive disease precisely

Relapsing-remitting MS, secondary progressive MS, and primary progressive MS describe different clinical courses. Current inflammatory activity adds another layer. Patients should ask for the course and activity assessment to be recorded clearly, with the observations supporting it. A referral that says only “MS” can leave the receiving clinician without information essential to interpreting previous treatment decisions.

The Chinese ocrelizumab prescribing information approved in March 2025 includes adult relapsing forms of MS, encompassing clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as adult primary progressive MS. This is evidence of an approved indication. It does not establish that a particular hospital has stock, that the medicine is appropriate for an individual, or that a payer will cover it. Chinese ocrelizumab prescribing information

Evidence continues to develop. The 2026 ORATORIO-HAND trial evaluated ocrelizumab in a broader primary progressive population and reported results concerning confirmed functional progression. The study should be read in terms of its participants, comparator, and endpoints. It does not demonstrate that all people with advanced disability will regain walking, nor does a new trial automatically change every national product label. ORATORIO-HAND original trial report

For a patient, a useful discussion translates this evidence into a realistic goal: reducing a particular risk over time, preserving a function that matters, or deciding that the treatment burden outweighs the likely benefit. The answer may remain uncertain. That uncertainty should be acknowledged explicitly and revisited with the results of follow-up.

Read new-drug announcements together with their safety requirements

In June 2026, the European Union authorized Cenrifki, containing tolebrutinib, for adults with secondary progressive MS who have had no relapses in the previous two years. Liver injury is an important part of its safety assessment and monitoring requirements. The absence of clinical relapses should not be assumed to mean that MRI shows no inflammatory activity. European Medicines Agency Cenrifki information

The US FDA had issued a complete response letter for the application in December 2025, raising concerns about serious liver injury and the benefit-risk assessment. These regulatory outcomes are jurisdiction-specific. Neither an EU authorization nor a US decision establishes approval, supply, or an appropriate treatment pathway in China. A patient considering travel for a new drug needs a verified local indication and a workable monitoring arrangement before making the trip. FDA original complete response letter

The same discipline applies to research headlines. A reduction in a trial endpoint is not necessarily recovery of established disability. A conference presentation does not by itself create a licensed treatment. If a clinic recommends something described as a breakthrough, ask for the exact intervention, the evidence relevant to your disease course, the applicable regulatory status, and the plan if a serious adverse event occurs.

Treat symptoms and rehabilitation goals alongside disease activity

Fatigue, urinary symptoms, spasticity, pain, sleep disturbance, and changes in mood or cognition can dominate everyday life. They deserve their own assessment even when a DMT appears to be controlling inflammatory activity. Describe what the symptom prevents you from doing and when it is most troublesome. This helps the team decide whether a medication review, rehabilitation assessment, sleep evaluation, or another intervention is appropriate.

Exercise and physical activity should be adapted to ability, preferences, fatigue, and safety. Published recommendations cover a broad range of disability and recognize the need for assistance or professional input in some situations. They do not justify one compulsory step target for everyone. A meaningful goal might be safer transfers, more reliable hand use, or enough endurance to participate in a family activity. Exercise and lifestyle physical-activity recommendations across the MS disease course

Keep track of the effort required for a task and how recovery feels afterward. If a programme leaves you unable to manage the following day, the team may need to adjust it. Family support should balance safety with autonomy. Taking over every task immediately after diagnosis can unnecessarily narrow a person's opportunities to remain active and involved.

Reserve invasive interventions for a defined purpose

Procedures may be considered for severe attacks or specific complications. Autologous haematopoietic stem-cell transplantation can also be discussed in carefully selected MS situations, but it involves intensive treatment and immune reconstitution. It is not equivalent to a generic stem-cell infusion advertised as replacing damaged myelin. Patient selection, centre expertise, and follow-up are central to the 2025 ECTRIMS and EBMT recommendations. ECTRIMS and EBMT AHSCT consensus

Ask what an intervention is intended to change and how that change will be measured. A procedure for a specific symptom does not necessarily modify the underlying disease course. Conversely, a treatment intended to suppress future inflammation may not immediately relieve fatigue. Clear goals help patients compare the likely benefit with hospitalization, adverse effects, rehabilitation needs, and the demands placed on family members.

Make a China treatment plan that continues after the visit

For a consultation in China, prepare original brain and spinal imaging, reports, a dated attack history, spinal-fluid findings, relevant antibody results, and a complete treatment record. Include medicines stopped because of adverse effects, the dates involved, and the response after stopping. A current prescription alone may conceal the information needed to understand an earlier treatment failure.

Before starting a new medicine, establish where blood tests and imaging will be performed, who reviews them, and how to report possible infection or relapse. Vaccine planning depends on the specific treatment and immune status. MS does not place every patient in an identical immunosuppression category, and patients should not stop DMT on their own to arrange vaccination. ECTRIMS and EAN vaccination consensus

Request an estimate tied to the actual proposed pathway, including assessment, administration, monitoring, and the handling of complications. Approval, hospital availability, and personal insurance coverage require separate confirmation. If a service or medicine has not been verified, keep it listed as unresolved. The most useful result of the visit is a plan that the patient and both treating teams can continue to carry out, with clear responsibilities when the situation changes.